EntryPoint Capital’s Kura Oncology KURA Stock Holding History

EntryPoint Capital’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-30,025	Closed	-$173K	–	786
2025 Q2	$173K	Buy	+30,025	New	+$184K	0.09%	513

Other funds holding KURA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

EntryPoint Capital's KURA Position: Q3 2025 in Review

EntryPoint Capital sold out of Kura Oncology (KURA) in Q3 2025, closing a stake of 30,025 shares — an estimated $173K sold.

EntryPoint Capital first reported a position in KURA in Q2 2025 and held it in 1 quarter. The position peaked at $173K in Q2 2025. 200 funds tracked by Wall St. Rank hold KURA as of Q3 2025.

EntryPoint Capital reported no remaining Kura Oncology position as of Q3 2025 after selling out during the quarter.
EntryPoint Capital sold 30,025 Kura Oncology shares in Q3 2025, an estimated $173K.
EntryPoint Capital first reported a position in Kura Oncology in Q2 2025 and held it in 1 quarter.
EntryPoint Capital's Kura Oncology position peaked at $173K in Q2 2025.
200 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2025.

Based on EntryPoint Capital's 13F filing for Q3 2025, filed 13 Nov 2025.